Cellectar biosciences enters into common stock agreements to raise $2.5 million priced at market under nasdaq rules

Florham park, n.j., june 05, 2025 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry into definitive agreements to raise $2.5 million from the sale of shares of the company's common stock priced at-market for nasdaq purposes. the closing of the offering is expected to occur on or about june 6, 2025, subject to satisfaction of customary closing conditions.
CLRB Ratings Summary
CLRB Quant Ranking